Journals / Klimik Dergisi / 2015 / Cilt: 28 - Sayı: 3

Evaluation of Candida Species and Risk Factors in Haematologic Cancer Patients With Candidemia

Kandidemi Saptanan Hematolojik Kanserli Hastalarda Etken Dağılımı ve Risk Faktörlerinin Değerlendirilmesi

Pages
117–121
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Caspofungin (33 patients, 57.9%) was the most frequently administered antifungal agent in candidemia, followed by amphotericin B (15 patients, 26.3%) and fluconazole (8 patients, 14%).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, agents of candidemia and predictive factors in patients with haematological malignancy are evaluated.Methods: All positive blood culture results of inpatients in haematology unit between January 2006 and December 2013 were determined using laboratory information system.
📊
Key Findings & Data:The data collected included demographic characteristics, underlying diseases, type of stem cell transplantation, absolute neutrophil counts, the causative Candida spp. and co-infecting fungi or bacteria, occurrence of chorioretinitis-endophthalmitis, occurrence of rash, antifungal therapies and risk factors like diabetes mellitus, dialysis, total parenteral nutrition, surgery, presence of central venous catheter and corticosteroid use.Results: In the 8-year period, among 1379 positive blood cultures, 67 (4.9%) were due to fungal species.
💡
Conclusion & Impact:Caspofungin (33 patients, 57.9%) was the most frequently administered antifungal agent in candidemia, followed by amphotericin B (15 patients, 26.3%) and fluconazole (8 patients, 14%).
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, agents of candidemia and predictive factors in patients with haematological malignancy are evaluated.Methods: All positive blood culture results of inpatients in haematology unit between January 2006 and December 2013 were determined using laboratory information system. Blood cultures in which Candida species grew were evaluated. The data collected included demographic characteristics, underlying diseases, type of stem cell transplantation, absolute neutrophil counts, the causative Candida spp. and co-infecting fungi or bacteria, occurrence of chorioretinitis-endophthalmitis, occurrence of rash, antifungal therapies and risk factors like diabetes mellitus, dialysis, total parenteral nutrition, surgery, presence of central venous catheter and corticosteroid use.Results: In the 8-year period, among 1379 positive blood cultures, 67 (4.9%) were due to fungal species. The agents were 57 (85.1%) Candida spp., 3 (4.5%) Aspergillus spp., 3 (4.5%) Trichosporon spp., 2 (3%) Saccharomyces spp. and 2 (3%) Geotrichium spp. Among the Candida species, the most frequently isolated species were non-albicans Candida (86%) dominated by C. tropicalis (51%). Five (8.7%) patients had a concomitant bacterial or fungal bloodstream infection other than Candida spp. The concomitant organisms included C. tropicalis and Enterococcus faecium (n=2), C. kefyr and Stenotrophomonas maltophilia (n=1), C. kefyr and Klebsiella sp. (n=1), and C. kefyr and C. glabrata (n=1). Caspofungin (33 patients, 57.9%) was the most frequently administered antifungal agent in candidemia, followed by amphotericin B (15 patients, 26.3%) and fluconazole (8 patients, 14%). Neutropenia (

Özet

Amaç: Bu çalışmada, hematolojik kanseri olan hastalarda kandidemi etkenlerinin ve risk faktörlerinin araştırılması amaçlanmıştır.Yöntemler: Hematoloji Servisi'nde Ocak 2006-Aralık 2013 arasında yatan hastaların tüm pozitif kan kültürleri laboratuvar bilgi yönetim sistemi yardımıyla saptanarak fungal etken üreyenler değerlendirilmiştir. Fungemik hastalara ait demografik özellik, altta yatan hastalık, yapılan kök hücre nakli tipi, mutlak nötrofil sayısı, etken olan Candida türü ve eşzamanlı üreyen mantar ya da bakteri türü, koryoretinit-endoftalmit varlığı, deri döküntüsü gelişmesi, kullanılan antifungal tedaviler, kan dışındaki eşzamanlı kültürlerle birlikte, diyabet, diyaliz, total parenteral nütrisyon, cerrahi, santral venöz kateter varlığı ve kortikosteroid kullanımı gibi risk faktörleri kaydedilmiştir.Bulgular: Sekiz yıllık dönemde 1379 pozitif kan kültürünün 67 (%4.9)'sinde fungal etken saptanmıştır. Etkenlerin 57 (%85.1)'si Candida spp., 3 (%4.5)'ü Aspergillus spp., 3 (%4.5)'ü Trichosporon spp., 2 (%3)'si Geotrichum spp. ve 2 (%3)'si de Saccharomyces spp. idi. Kan kültüründe üreyen 57 Candida türünün 49 (%86)'u C. albicans dışı Candida türleri olup en sık olarak C. tropicalis (%51) saptanmıştır. Beş (%8.7) hastada eşzamanlı bakteriyel ya da Candida dışı fungal etkene bağlı kan dolaşımı infeksiyonu görülmüştür. Eşzamanlı mikroorganizmalar C. tropicalis ile Enterococcus faecium (n=2), C. kefyr ile Stenotrophomonas maltophilia (n=1), C. kefyr ile Klebsiella sp. (n=1) ve C. kefyr ile C. glabrata (n=1)'dır. Kandidemi tedavisinde en sık kullanılan antifungaller sırasıyla, 33 (%57.9) olguyla kaspofungin, 15 (%26.3) olguyla amfoterisin B ve 8 (%14) olguyla flukonazoldür. C. albicans dışı Candida türleri ve kandideminin nötropeni (

🔖

Cite This Article

ÇİFTÇİOĞLU, A., SARICAOĞLU, E. M., AKAN, H., YILMAZ, G., GÜNDÜZ, M., ÖZEN, M. (2022). Evaluation of Candida Species and Risk Factors in Haematologic Cancer Patients With Candidemia. Klimik Dergisi, Cilt: 28 - Sayı: 3, 117–121. https://ajindex.com/articles/573618

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008; 32(Suppl. 2): S87-91. [CrossRef] Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012; 73(1): 45-8. [CrossRef] Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA. Emerg Infect Dis. 2015; 21(11): 1942-50. [CrossRef] Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One. 2014; 9(7): e101510. [CrossRef] Girmenia C, Finolezzi E, Federico V, Santopietro M, Perrone S. Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011013. [CrossRef] Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol. 2009; 27(20): 3398-409. [CrossRef] Cugno C, Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep. 2012; 4(1): e9. [CrossRef] Nace HL, Horn D, Neofytos D. Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007. Diagn Microbiol Infect Dis. 2009; 64(3): 289-94. [CrossRef] Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004- 2008. Diagn Microbiol Infect Dis. 2012; 74(4): 323-31. [CrossRef] Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006; 91(8): 1068-75.
  2. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009; 48(12): 1695-703. [CrossRef] Kaya D, Kaptanoğlu S, Üstüner Z, Ertör O. Nötropenik hasta örneklerinden izole edilen mayaların tiplendirilmesi ve flukonazole karşı direncin araştırılması. Klimik Derg. 2001; 14(1): 14-6.
  3. Şahin E, Ersöz G, Otağ F, et al. Hematolojik malignit